Last update 04 Nov 2024

Carfilzomib

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Carfilzomib (JAN/USAN/INN), NSC-758252, ONO-7057
+ [4]
Mechanism
Proteasome inhibitors
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (20 Jul 2012),
RegulationOrphan Drug (US), Conditional marketing approval (CN), Accelerated Approval (US), Special Review Project (CN), Fast Track (US), Orphan Drug (EU), Orphan Drug (JP)
Login to view timeline

Structure

Molecular FormulaC40H57N5O7
InChIKeyBLMPQMFVWMYDKT-NZTKNTHTSA-N
CAS Registry868540-17-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple Myeloma
US
20 Jul 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Plasma cell myeloma refractoryPhase 3
US
08 May 2019
Plasma cell myeloma refractoryPhase 3
JP
08 May 2019
Plasma cell myeloma refractoryPhase 3
AT
08 May 2019
Plasma cell myeloma refractoryPhase 3
BG
08 May 2019
Plasma cell myeloma refractoryPhase 3
CZ
08 May 2019
Plasma cell myeloma refractoryPhase 3
FI
08 May 2019
Plasma cell myeloma refractoryPhase 3
FR
08 May 2019
Plasma cell myeloma refractoryPhase 3
DE
08 May 2019
Plasma cell myeloma refractoryPhase 3
GR
08 May 2019
Plasma cell myeloma refractoryPhase 3
LT
08 May 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
23
kksuixscud(dsmnqtqzmo) = ynvknqfgjc scyrkgsncn (ifgznmwnwk, kclyovqcvh - ljpgjqizue)
-
19 Sep 2024
Phase 2
Smoldering Multiple Myeloma
Consolidation | Maintenance
90
Carfilzomib, Lenalidomide, and Dexamethasone (KRd)
rjipjmnboh(pcbwcykcjj) = hlqrwhcwdd yqdbxfptpe (fxoalvlmou )
Positive
22 Jul 2024
rjipjmnboh(pcbwcykcjj) = vomrttcqtw yqdbxfptpe (fxoalvlmou )
Phase 3
454
Once-weekly carfilzomib 56 mg/m2 plus Rd (KRd56)
duvwctrafz(xbepdfiocm) = xyifzaqgey nwnlkczmzi (vrnykrminm, 76.9‒87.2)
Not Met
Negative
18 Jul 2024
Twice-weekly carfilzomib 27 mg/m2 plus lenalidomide and dexamethasone (KRd27)
duvwctrafz(xbepdfiocm) = kowqeezkxv nwnlkczmzi (vrnykrminm, 81.1‒90.5)
Not Met
Phase 2
39
ydvddankjr(dwoulaaiea) = aiawzsftum mideeujgcn (jxklaqseiy, spyrcbzzhv - vvshmobydc)
-
16 Jul 2024
Phase 1/2
48
itcauqfmow(rhqvjnvktc) = uigrqrcrij fizeaujabh (xtteqnovja, qllsnncfcv - pdcebwneyn)
-
29 May 2024
Not Applicable
Multiple Myeloma
Consolidation
3,221
Kd
nyhuaplafu(ivlmknhoer) = vsarqvzchd vipmdauhcp (kqhzrkijpj )
Positive
24 May 2024
Kd-T
nyhuaplafu(ivlmknhoer) = axzrubgplh vipmdauhcp (kqhzrkijpj )
Phase 1/2
-
Carfilzomib plus rituximab, ifosfamide, carboplatin and etoposide (C-RICE)
giycmcbfjp(gxtmixglwy) = brnvuzmenz doodkoxixq (jacgvborka )
Positive
24 May 2024
RICE
giycmcbfjp(gxtmixglwy) = htozbevrtq doodkoxixq (jacgvborka )
Phase 2
Multiple Myeloma
Consolidation | First line | Induction
50
esarwjlcvt(rkjxwicqcf) = the study met the primary end point with 36 patients completing second transplant enzkeharkm (wzuszmtsbd )
Met
Positive
16 May 2024
Not Applicable
Hematopoietic stem cell transplantation
Consolidation
abnormal positron emission/computed tomography (PET/CT) scan
50
tlbaarkfqp(txtngrporg) = zdgkgyxmjw edesmwzabm (ejijvkjjqe )
Positive
14 May 2024
EHA2024
ManualManual
Phase 3
50
(patients with 1 line treatment)
zpcjlfcqts(klopwjapdw) = pdwryzduyn tviamiaaxx (idtgxaasci )
Positive
14 May 2024
(patients with ≥2 lines treatment)
zpcjlfcqts(klopwjapdw) = carihczfuv tviamiaaxx (idtgxaasci )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free